Skip to main content
Clinical Trials/NCT03981484
NCT03981484UnknownPhase 2

REPlaCE- Randomized Trial Evaluating the Use of Prothrombin Complex concEntrate to Improve Survival in Patients With Traumatic Coagulopathy

Bellal A. Joseph, MD, FACS0 sites280 target enrollmentStarted: January 2020Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 2
Sponsor
Enrollment
280
Primary Endpoint
24 Hour Mortality

Study Overview

Brief Summary

Uncontrolled hemorrhage continues to be a significant source of mortality for trauma patients. Their condition is further complicated by Trauma Induced Coagulopathy (TIC), which makes it more difficult to control bleeding due to coagulation factor deficiency. Prothrombin Complex Concentrate (PCC) is thought to be a promising treatment option. This phase II clinical trial evaluates the use of 4-Factor PCC in addition to standard resuscitation methods compared to standard resuscitation methods alone in patients with TIC. Patients will be randomized at a 1:1 ratio. The primary endpoint of this trial will be 30 day mortality.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
15 Years to — (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • ≥15 years old
  • anticipate giving 4+ units based on Revised Assessment of Bleeding and Transfusion score ≥ 2

Exclusion Criteria

  • Cardiopulmonary Resuscitation > 5 minutes
  • Penetrating cranial injury or exposed brain matter
  • Anticoagulation treatment
  • Transfer patients
  • Known pregnancy

Arms & Interventions

Standard of Care

Active Comparator

standard resuscitation methods only

Intervention: Whole Blood, Plasma, Packed Red Blood Cells (Biological)

PCC

Experimental

single dose of 4-Factor PCC in addition to standard resuscitation methods

Intervention: Prothrombin Complex Concentrate (Biological)

Outcomes

Primary Outcomes

24 Hour Mortality

Time Frame: 24 hours after enrollment

Assess if patient is alive at 24 hours post treatment

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Bellal A. Joseph, MD, FACS
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Bellal A. Joseph, MD, FACS

Chief of the Division of Trauma, Acute Care, Burn, and Emergency Surgery

University of Arizona

Similar Trials